News
LABT
0.6680
-1.04%
-0.0070
Weekly Report: what happened at LABT last week (0525-0529)?
Weekly Report · 5d ago
Lakewood-Amedex Biotherapeutics building broad antimicrobial platform, CEO says
TipRanks · 05/29 18:11
Lakewood-Amedex CEO says going public boosts visibility, engagement
TipRanks · 05/29 18:10
Bisphosphocin technology offers differentiated approach, Cooper says
TipRanks · 05/29 18:09
Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper
TipRanks · 05/29 18:05
Lakewood-Amedex Biotherapeutics issued two new patents
TipRanks · 05/27 14:34
Lakewood-Amedex Biotherapeutics Expands Global Intellectual Property Portfolio With Issuance Of Two Patents, One Each In Australia And New Zealand Respectively
Benzinga · 05/27 12:07
Lakewood-Amedex wins Australia, New Zealand patents for Nu-3 diabetic foot ulcer gel formulation
PUBT · 05/27 12:04
Weekly Report: what happened at LABT last week (0518-0522)?
Weekly Report · 05/25 10:53
Lakewood-Amedex Q1 FY26 net loss widens to $923,291
PUBT · 05/22 20:55
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 05/20 17:05
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
Benzinga · 05/18 14:11
Lakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down
NASDAQ · 05/18 13:56
Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3
TipRanks · 05/18 12:12
Lakewood-Amedex Biotherapeutics Reports Nu-3 Data And Completes Key Manufacturing Milestones Ahead oO Planned Phase 2 Trial For Diabetic Foot Ulcer Treatment
Benzinga · 05/18 12:08
Lakewood-Amedex advances Nu-3 gel toward Phase 2 trial in infected diabetic foot ulcers
PUBT · 05/18 12:05
LAKEWOOD-AMEDEX BIOTHERAPEUTICS : KEY FORMULATION, DELIVERY AND MANUFACTURING STEPS COMPLETED IN PREPARATION FOR PLANNED PHASE 2 CLINICAL TRIAL
Reuters · 05/18 12:02
LAKEWOOD-AMEDEX BIOTHERAPEUTICS ANNOUNCES POSITIVE DATA FOR THE ADVANCEMENT OF LEAD CANDIDATE, NU-3, IN INFECTED DIABETIC FOOT ULCERS
Reuters · 05/18 12:02
Weekly Report: what happened at LABT last week (0511-0515)?
Weekly Report · 05/18 10:52
Lakewood-Amedex Biotherapeutics Inks Agreement To Serve As Contract Research Organization For Professional Education And Research Institute's Upcoming Phase 2 Clinical Program Of Nu-3
Benzinga · 05/12 12:11
More
Webull provides a variety of real-time LABT stock news. You can receive the latest news about Lakewood-Amedex through multiple platforms. This information may help you make smarter investment decisions.
About LABT
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.